​

Avidity Biosciences (RNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNA Stock Forecast

Avidity Biosciences (RNA) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $74.44, with a high of $96.00 and a low of $70.00. This represents a 6.45% increase from the last price of $69.93.

$5 $24 $43 $62 $81 $100 High: $96 Avg: $74.44 Low: $70 Last Closed Price: $69.93

RNA Stock Rating

Avidity Biosciences stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (55.00%), 9 Hold (45.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 9 11 Strong Sell Sell Hold Buy Strong Buy

RNA Price Target Upside V Benchmarks

TypeNameUpside
StockAvidity Biosciences6.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts7910
Avg Price Target$72.00$73.56$73.20
Last Closing Price$69.93$69.93$69.93
Upside/Downside2.96%5.19%4.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25513---18
Sep, 25513---18
Aug, 25513---18
Jul, 25611---17
Jun, 2568---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025Keay NakaeChardan Capital$72.00$70.002.86%2.96%
Oct 28, 2025Luca IssiRBC Capital$72.00$70.002.86%2.96%
Oct 28, 2025Keay NakaeLoop Capital Markets$72.00$70.002.86%2.96%
Oct 27, 2025Market PerformLeerink Partners$72.00$69.952.93%2.96%
Oct 27, 2025Boobalan PachaiyappanRoth Capital$72.00$49.1546.49%2.96%
Oct 27, 2025Market PerformBernstein$72.00$49.1546.49%2.96%
Oct 27, 2025H.C. Wainwright$72.00$49.1546.49%2.96%
Sep 17, 2025Roth Capital$62.00$40.0654.77%-11.34%
Sep 10, 2025Eric SchmidtCantor Fitzgerald$96.00$46.40106.90%37.28%
Jul 11, 2025Gavin Clark-GartnerEvercore ISI$70.00$31.45122.58%0.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2025Cowen & Co.BuyHolddowngrade
Oct 28, 2025RBC CapitalSector Performdowngrade
Oct 27, 2025CitigroupBuyNeutraldowngrade
Oct 27, 2025Roth CapitalNeutraldowngrade
Oct 27, 2025CitigroupBuyBuyhold
Oct 27, 2025NeedhamBuyHolddowngrade
Oct 27, 2025Raymond JamesStrong BuyMarket Performdowngrade
Oct 27, 2025BernsteinOutperformMarket Performdowngrade
Oct 27, 2025H.C. WainwrightBuyNeutraldowngrade
Sep 12, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.83$-3.24$-2.91$-2.89----
Avg Forecast$-1.80$-2.73$-3.36$-2.65$-2.87$-3.30$-3.57$-1.85$1.53
High Forecast$-1.39$-2.11$-2.07$-1.86$-2.70$-2.45$-2.17$-0.03$2.24
Low Forecast$-2.20$-3.34$-4.83$-2.98$-2.99$-4.49$-4.63$-3.20$0.81
Surprise %12.78%3.66%-3.57%9.81%0.70%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.79M$9.33M$9.22M$9.56M$10.90M----
Avg Forecast$5.47M$9.51M$8.32M$19.58M$9.74M$7.11M$21.89M$307.80M$861.96M
High Forecast$6.42M$11.16M$11.13M$46.62M$12.09M$9.67M$22.88M$418.75M$1.17B
Low Forecast$4.53M$7.87M$5.87M$5.92M$7.46M$4.54M$20.90M$196.62M$550.63M
Surprise %23.96%-1.98%10.84%-51.17%11.87%----

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.98M$-117.37M$-169.08M$-212.22M$-322.30M----
Avg Forecast$-131.18M$-199.05M$-245.03M$-212.22M$-207.69M$-253.46M$-248.49M$-118.09M$111.56M
High Forecast$-101.73M$-154.36M$-151.35M$-136.14M$-197.17M$-179.08M$-158.64M$-2.51M$163.85M
Low Forecast$-160.58M$-243.66M$-352.61M$-217.24M$-218.20M$-327.84M$-338.34M$-233.67M$59.18M
Surprise %-66.47%-41.03%-31.00%-55.19%----

RNA Forecast FAQ

Is Avidity Biosciences stock a buy?

Avidity Biosciences stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Avidity Biosciences is a favorable investment for most analysts.

What is Avidity Biosciences's price target?

Avidity Biosciences's price target, set by 20 Wall Street analysts, averages $74.44 over the next 12 months. The price target range spans from $70 at the low end to $96 at the high end, suggesting a potential 6.45% change from the previous closing price of $69.93.

How does Avidity Biosciences stock forecast compare to its benchmarks?

Avidity Biosciences's stock forecast shows a 6.45% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Avidity Biosciences over the past three months?

  • October 2025: 27.78% Strong Buy, 72.22% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 27.78% Strong Buy, 72.22% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 27.78% Strong Buy, 72.22% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Avidity Biosciences’s EPS forecast?

Avidity Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.3, marking a 14.19% increase from the reported $-2.89 in 2024. Estimates for the following years are $-3.57 in 2026, $-1.85 in 2027, and $1.53 in 2028.

What is Avidity Biosciences’s revenue forecast?

Avidity Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $7.11M, reflecting a -34.79% decrease from the reported $10.9M in 2024. The forecast for 2026 is $21.89M, followed by $307.8M for 2027, and $861.96M for 2028.

What is Avidity Biosciences’s net income forecast?

Avidity Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-253M, representing a -21.36% decrease from the reported $-322M in 2024. Projections indicate $-248M in 2026, $-118M in 2027, and $111.56M in 2028.